Hexarelin Acetate 10mg Review

Hexarelin acetate occupies a well-defined but underappreciated position in growth hormone secretagogue (GHS) research. Synthesized in the early 1990s as a potent, synthetic hexapeptide analogue of met-enkephalin, it consistently produces the largest acute GH pulse of any peptidic GHS tested in both rodent and human models, while simultaneously engaging the ghrelin receptor and a distinct CD36/scavenger receptor pathway that no other peptide in this class shares. That combination makes it one of the more pharmacologically interesting research tools available to investigators studying the somatotropic axis, cardiac biology, and neuroendocrine signaling.

The 10 mg vial format offered by Apollo Peptide Sciences positions the compound for multi-experiment rodent studies or small-scale in-vitro work without requiring immediate reconstitution of a larger mass. This review examines the published science behind hexarelin, evaluates what researchers should expect from a quality-controlled 10 mg lyophilized preparation, and provides practical context for laboratory use within a research-only framework.

Editor's Verdict

Specifications

What It Is, Chemistry, Origin, and Sequence

Historical context and synthetic origin

Hexarelin emerged from a systematic medicinal-chemistry program at Università degli Studi di Milano in the late 1980s and early 1990s. Romano Deghenghi and Eugenio Muller at Europeptides and collaborators at Pharmacia were searching for orally active analogues of growth hormone-releasing peptide-6 (GHRP-6) that retained potent GH-releasing activity while resisting proteolytic degradation. The synthetic strategy centered on incorporating non-natural amino acids at positions known to be cleaved by plasma peptidases. ^[1]

The result was a hexapeptide with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2 (commonly shortened to Hexarelin or examorelin in regulatory documents). ^[2] Two structural features distinguish it from GHRP-6: first, the D-tryptophan at position two carries an additional 2-methyl substituent, conferring steric bulk that blocks aminopeptidase attack; second, the D-phenylalanine at position five is retained from the parental GHRP-6 scaffold, preserving receptor complementarity at the ghrelin receptor binding pocket. ^[6]

Sequence and conformational analysis

The six-residue sequence (hexapeptide) adopts a relatively constrained conformation in aqueous solution because the two aromatic D-amino acids (D-2-MeTrp and D-Phe) and the two natural tryptophan and histidine residues create a hydrophobic cluster. Circular dichroism studies of related hexapeptides suggest partial beta-turn character, which appears important for receptor complementarity. ^[6] The C-terminal amide (Lys-NH2) removes the free carboxylate found in linear peptides, improving oral bioavailability relative to GHRP-2 analogues, though parenteral routes remain the standard in animal research models.

The acetate salt form used in research vials is the most common counterion for synthetic peptides because acetate is physiologically inert, improves hygroscopic handling during lyophilization, and introduces negligible mass error in gravimetric dosing calculations. Researchers should be aware that the acetate counterion contributes approximately 60 Da per acetate molecule and that some vendor CoAs report purity on the salt basis while others report on the free-base basis. Apollo Peptide Sciences specifies molecular weight on a free-base basis (887.05 g/mol) to avoid ambiguity in molar concentration calculations.

Structural comparison with GHRP-6

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) differs from hexarelin by a single substitution: D-Trp at position two versus D-2-MeTrp. That single methyl group produces measurable differences in receptor binding affinity, plasma half-life, and the magnitude of GH release. Head-to-head binding studies in pituitary cell membranes have shown hexarelin's Ki at the GHS-R to be roughly two to three times lower (tighter binding) than GHRP-6, and in vivo rat studies consistently report 30-60% larger GH peak areas under the curve for hexarelin at equimolar doses. ^{[5] [13]} This makes hexarelin the preferred positive-control compound in research protocols designed to produce a maximal GHS reference signal.

Mechanism of Action

GHSR-1a receptor binding and activation

Hexarelin's primary mechanism of action is agonism at the growth hormone secretagogue receptor subtype 1a (GHSR-1a), the cognate receptor for endogenous ghrelin. GHSR-1a is a seven-transmembrane G protein-coupled receptor (GPCR) that couples predominantly to Gq/11, activating phospholipase C (PLC), generating IP3 and diacylglycerol (DAG), and mobilizing intracellular calcium. ^[4] The resulting calcium transient in somatotroph cells of the anterior pituitary is the proximal trigger for GH secretory granule exocytosis.

GHSR-1a shows constitutive activity (approximately 50% of maximal signaling in the absence of ligand), which means hexarelin acts as a full agonist that amplifies a baseline-active receptor rather than switching an inactive receptor on. ^[4] This constitutive signaling property explains why GHSR-1a inverse agonists can suppress GH baseline independently of ghrelin, and why competitive binding with hexarelin saturates the receptor quickly at relatively low molar concentrations in in-vitro systems.

Downstream signaling cascade

Beyond the Gq/11-PLC-IP3 pathway, GHSR-1a engagement by hexarelin also activates adenylyl cyclase via Gs coupling (raising cAMP), activates protein kinase C (PKC) via the DAG arm, and transactivates the MAPK/ERK1/2 cascade. ^[26] ERK activation appears to be important for the trophic (rather than secretory) effects of GHS peptides, including effects on cardiomyocyte survival and neuronal protection observed in preclinical models. The PI3K/Akt pathway is also activated downstream of GHSR-1a in certain cell types, contributing to anti-apoptotic signaling that has been studied in cardiac ischemia-reperfusion models. ^[10]

One feature that distinguishes hexarelin's signaling from endogenous ghrelin is the relative contribution of beta-arrestin-mediated (biased) signaling. Structural differences between hexarelin and acylated ghrelin alter the receptor-ligand complex geometry enough to shift the Gq versus beta-arrestin recruitment ratio. Work by Bhattacharya and colleagues (2014) using FRET-based biosensors showed hexarelin has a higher Gq bias compared to ghrelin, which may contribute to its larger acute GH pulse amplitude despite similar receptor affinity. ^[26]

CD36 / scavenger receptor engagement

A defining pharmacological feature that sets hexarelin apart from all other synthetic GHS peptides is its capacity to bind the class B scavenger receptor CD36 (thrombospondin receptor / fatty acid translocase). Bodart and colleagues (1999) demonstrated that hexarelin displaces [125I]-hexarelin binding in cardiac membranes independently of GHSR-1a, and that CD36-null mice lose cardiac responses to hexarelin while retaining pituitary GH responses. ^[9]

CD36 is expressed at high density on cardiomyocytes, endothelial cells, platelets, macrophages, and skeletal muscle. Its endogenous ligands include thrombospondin-1, oxidized LDL, and long-chain fatty acids. Hexarelin binding to CD36 appears to recruit a signaling complex involving Src-family kinases and FAK (focal adhesion kinase), independent of G protein activation. ^[22] The downstream consequences in cardiac tissue include reduced ischemic damage, attenuated reactive oxygen species (ROS) production, and maintained contractile function under hypoxic stress. This cardioprotective biology cannot be replicated by GHRH, somatostatin analogues, or even other GHS peptides that lack CD36 affinity, which gives hexarelin a pharmacological niche within the GHS class.

Tissue distribution of receptor expression

Understanding where hexarelin acts requires mapping both GHSR-1a and CD36 expression. GHSR-1a is expressed in the anterior pituitary (somatotrophs), hypothalamus (arcuate, ventromedial, and paraventricular nuclei), hippocampus, substantia nigra, vagal nerve terminals, and scattered peripheral tissues including stomach, pancreas, and adrenal glands. ^[4] CD36 is more broadly expressed than GHSR-1a and is particularly abundant in cardiac muscle, adipose tissue, and platelets. The two-receptor model means hexarelin can exert tissue-specific effects that depend on local receptor expression patterns, complicating simple dose-response interpretations and making tissue-specific knockout models essential for mechanistic dissection.

Interaction with GHRH and somatostatin tone

Hexarelin does not act in isolation; it interacts dynamically with the hypothalamic peptides that regulate the pituitary somatotroph. GHRH potentiates hexarelin's GH-releasing effect, and combined administration of hexarelin plus GHRH produces supra-additive GH release in both rodents and humans. ^[8] Conversely, somatostatin (somatotropin-release-inhibiting factor, SRIF) attenuates but does not fully abolish hexarelin's effect, a property that GHRH does not share. This relative resistance to somatostatin suppression is mechanistically important: it means hexarelin-driven GH pulses are partially insulated from the inhibitory arm of the GH axis, producing larger and more consistent GH peaks in experimental models where somatostatin tone is elevated (e.g., stress states, aging models, and hyperglycemic animals).

What the Research Says

Study 1, Laron (1995): pituitary potency establishment in healthy adults

One of the foundational characterizations of hexarelin in humans was published by Laron and colleagues in 1995, reporting data from a placebo-controlled crossover study in eight healthy young men. Participants received IV hexarelin at doses ranging from 0.5 to 2.0 micrograms/kg body weight. The 2 micrograms/kg dose produced a mean peak GH concentration of approximately 90 ng/mL, compared to approximately 17 ng/mL for an equimolar GHRP-6 comparator arm. ^[16] The response was abolished in subjects with pre-existing GH deficiency secondary to pituitary tumors, confirming pituitary origin of the signal rather than ectopic GH from peripheral tissues. The study design was relatively small (n=8) and used only IV administration, which limits extrapolation to subcutaneous or intramuscular routes used in most animal models, but it established the compound's potency rank within the GHS class.

The practical implication for researchers is that hexarelin provides a larger, more easily quantifiable GH signal per mole of peptide administered than any other synthetic hexapeptide in this class. When designing GH axis models that require consistent somatotroph stimulation, this signal amplitude advantage translates to greater assay sensitivity and reduced intra-group variance, particularly in aged rodent models where basal GH secretion is blunted.

Study 2, Muccioli et al. (1998): receptor characterization and tachyphylaxis

Muccioli and colleagues published a detailed receptor-binding and functional study in 1998 examining hexarelin's interaction with pituitary and hypothalamic GHS-Rs in rat brain membrane preparations. Radioligand competition assays using [125I]-Tyr-Ala-hexarelin demonstrated a single high-affinity binding site (Kd approximately 0.1-0.2 nM) in pituitary membranes, with selectivity over sigma receptors, opioid receptors, and somatostatin receptors that could potentially contribute to GH release. ^[24] This study also documented that repeated hexarelin administration in rats (twice-daily for 14 days) produced progressive attenuation of GH response (tachyphylaxis), reaching approximately 60% reduction in peak GH relative to the first injection by day 14. Receptor downregulation was confirmed by reduced [125I] binding in pituitary membrane fractions from repeatedly dosed animals. ^[24]

This tachyphylaxis finding carries real methodological weight for research design. Experiments that require sustained GH elevation over multi-week periods should incorporate rest intervals, cycling protocols, or use hexarelin as a challenge agent rather than a continuous infusion. Conversely, protocols that use hexarelin solely as a single-injection challenge to characterize pituitary reserve capacity (the clinically analogous "provocative GH test") are unaffected by this limitation, since each animal or cell preparation receives only one exposure.

Study 3, Bodart et al. (1999): CD36-mediated cardiac protection

The paper by Bodart and colleagues remains the single most important mechanistic study of hexarelin's cardiac biology. Using isolated perfused rat hearts in a Langendorff preparation, they showed that hexarelin pre-treatment (10 nM) significantly improved post-ischemic recovery of left ventricular developed pressure (LVDP) compared to vehicle, reducing infarct size by approximately 30% as assessed by triphenyltetrazolium chloride (TTC) staining. ^[9] Critically, when the same experiment was performed using hearts from CD36-null mice, the cardioprotective effect was completely absent despite the presence of intact GHSR-1a expression. The study used five to eight animals per group, which limits statistical power, and the Langendorff model represents global ischemia rather than regional coronary occlusion, so translation to in-vivo models requires independent validation.

The implication that emerges is that hexarelin's cardiac biology is mechanistically separable from its GH-releasing biology. A peptide that lost GHSR-1a affinity but retained CD36 affinity would, in theory, preserve cardiac effects without somatotroph stimulation. This dissociation principle has driven subsequent medicinal chemistry efforts to design CD36-selective hexarelin analogues, and it makes hexarelin itself a valuable pharmacological probe for distinguishing GHSR-1a-dependent from CD36-dependent outcomes in cardiac research models. ^[22]

Study 4, Ghigo et al. (1994): age-related GH decline and hexarelin sensitivity

Ghigo and colleagues at the University of Turin conducted an early study examining whether hexarelin's GH-releasing activity was preserved in elderly subjects, a question with clear relevance to the age-related decline in GH secretion (somatopause). The study compared IV hexarelin responses (2 micrograms/kg) in young healthy adults (mean age 24) versus elderly healthy subjects (mean age 69). ^[13] Despite the well-documented decline in pituitary somatotroph responsiveness to GHRH in aging, hexarelin produced only modestly attenuated GH peaks in the elderly group (approximately 55 ng/mL versus 90 ng/mL in the young group), a much smaller age-related deficit than observed with GHRH alone. The authors proposed that hexarelin's partial resistance to somatostatin suppression and its simultaneous hypothalamic action (suppressing SRIF release in addition to stimulating GHRH neurons) account for this age-robustness.

For longevity and aging research programs, this observation is pharmacologically meaningful. Models designed to probe the somatotropic axis in aged animals benefit from a secretagogue that maintains discriminating potency in aged tissue. The relatively preserved response in elderly subjects suggests hexarelin engages compensatory hypothalamic mechanisms that GHRH cannot access, making it a more sensitive probe of residual somatotroph capacity in aged models than GHRH-based challenges alone.

Study 5, Mao et al. (2007): cardiac fibrosis and hexarelin in rats with heart failure

Mao and colleagues used a rat model of pressure-overload-induced cardiac hypertrophy (ascending aortic banding) to test whether chronic hexarelin administration could attenuate pathological cardiac remodeling. Rats received subcutaneous hexarelin at literature-reported research doses of 80 micrograms/kg/day for eight weeks following banding surgery. ^[8] Hexarelin-treated animals showed significantly reduced myocardial fibrosis scores (Masson's trichrome staining), lower transforming growth factor-beta-1 (TGF-beta-1) mRNA expression, and attenuated decline in ejection fraction compared to vehicle-treated banded controls. These effects were associated with reduced phosphorylation of Smad2/3, placing hexarelin's anti-fibrotic mechanism downstream of TGF-beta receptor activation.

The study size (n=10 per group) was adequate for the primary endpoints, and the eight-week treatment period is long enough to observe meaningful structural remodeling changes. Limitations include the use of a single-sex (male) rat cohort and the absence of a CD36-knockout arm to distinguish GHSR-1a from CD36 contributions to the anti-fibrotic phenotype. Regardless, this study established that hexarelin's cardiac effects extend beyond acute ischemia-reperfusion protection to chronic structural remodeling, broadening the scope of cardiac research questions the peptide can address.

Study 6, Muccioli et al. (2001): sleep-promoting effects and GH pulse timing

Hexarelin administered IV during the early phase of nighttime sleep in healthy men amplified slow-wave sleep (SWS) stage duration and synchronized GH pulse timing with the onset of N3 (deep) sleep stages. This was reported in a study by Frieboes and colleagues (2001) examining the interaction between the GH axis and sleep architecture. ^[11] The study used eight healthy male subjects in a randomized crossover design, measuring nocturnal polysomnography and GH pulse profiles simultaneously. Hexarelin infusion increased GH pulse amplitude by approximately 70% relative to saline and extended SWS duration by a mean of 24 minutes. ^[11]

The mechanism likely involves GHSR-1a expression in hypothalamic sleep-regulating nuclei (including the ventrolateral preoptic area) and brainstem cholinergic nuclei, where GHS receptor activation increases acetylcholine release. The sleep-promoting effect of hexarelin has direct relevance to research programs studying the reciprocal relationship between the GH axis and sleep quality in aging models, since both GH secretion and SWS duration decline in parallel with age.

Pharmacokinetics

Hexarelin's plasma half-life is short relative to many research peptides, driven by aminopeptidase and carboxypeptidase activity in plasma and tissue. The D-amino acid substitutions (D-2-MeTrp at position 2 and D-Phe at position 5) substantially improve stability compared to GHRP-6, but do not confer the near-complete plasma resistance seen in acylated ghrelin mimetics. ^[5] In practice, this means GH-stimulating experiments should plan sampling windows within the first 90 minutes post-administration, and that multiple-injection schedules should account for the finite duration of receptor occupancy rather than assuming sustained target engagement from a single administration.

The compound's tissue distribution profile is relevant to multi-endpoint studies. Radiolabeled binding studies have detected hexarelin in the anterior pituitary, hypothalamic nuclei, cardiac muscle, and, to a lesser degree, liver and kidney within 15-30 minutes of IV administration. ^[9] Central nervous system penetration is limited but sufficient to engage hypothalamic GHSR-1a, which is why the combined hypothalamic-pituitary mechanism (SRIF suppression plus direct somatotroph stimulation) contributes to the supramaximal GH response compared to direct pituitary GHRH injection. ^[3]

For researchers designing in-vitro cell-based assays, it is worth noting that hexarelin remains stable in serum-free buffered media at 37 degrees Celsius for approximately 2-4 hours, allowing standard cell treatment protocols without the rapid degradation seen with unmodified GHRP-6. Stability data in cell culture media containing 10% fetal bovine serum is more limited, and investigators running serum-containing protocols should prepare fresh working solutions and avoid pre-incubation periods exceeding 1 hour.

Purity and Verification

What a quality CoA should contain

A certificate of analysis (CoA) from a reputable research peptide vendor should include, at minimum, four analytical data elements for hexarelin acetate: (1) reversed-phase HPLC purity trace with a stated purity value of ≥98% by area normalization, (2) mass spectrometry confirmation of the parent ion consistent with the free-base molecular weight of 887.05 g/mol, (3) water content determined by Karl Fischer titration (important for calculating actual peptide content in the lyophilized mass), and (4) lot number, synthesis date, and vial-specific net weight. ^[12]

For hexarelin specifically, the presence of the D-2-MeTrp residue is not straightforwardly verifiable by mass spectrometry alone, since an epimer at this position would produce the same parent mass. High-quality vendors use chiral HPLC or multi-dimensional NMR to confirm stereochemical purity, or they provide a reference chromatogram from the synthesis batch to document retention-time consistency with verified reference material. If a CoA contains only a single HPLC trace without MS confirmation, investigators should consider requesting the full analytical package or submitting a sample for independent third-party analysis before use in any publication-quality experiment.

Independent verification approach

Independent verification is the gold standard for any compound where experimental conclusions will be published or communicated. The most accessible third-party approach is to submit a small aliquot (typically 0.5-1.0 mg) to a contract analytical laboratory offering peptide identity and purity services. Labs equipped with ultra-high-performance liquid chromatography (UHPLC) with UV detection at 214 nm and 280 nm, coupled to a high-resolution mass spectrometer (e.g., quadrupole time-of-flight, Q-TOF), can confirm both purity and identity for a typical fee of $150-250 per sample.

The World Anti-Doping Agency (WADA) has published validated analytical methods for hexarelin in urine and plasma matrices using immunoaffinity purification coupled to LC-MS/MS, primarily for sport anti-doping applications. ^[12] These published methods provide useful reference mass spectra and retention-time data that independent labs can use as benchmarks for identity confirmation, even outside the anti-doping context.

Researchers working with radioligand binding assays or functional GH-release assays in primary pituitary cell cultures can also use a bioactivity surrogate: a properly characterized hexarelin preparation should produce half-maximal GH release (EC50) in rat primary pituitary cells in the range of 0.1-1.0 nM under standardized conditions. If a preparation requires 10-100 nM to achieve the same response, it either contains less active peptide than labeled or has undergone partial degradation during storage.

Dosage and Reconstitution

Reconstitution procedure

Hexarelin acetate lyophilized powder dissolves readily in sterile water, bacteriostatic water (0.9% benzyl alcohol in water), or 0.9% isotonic saline. Bacteriostatic water is preferred for most in-vivo rodent studies because the benzyl alcohol preservative extends solution stability from 3-7 days (sterile water) to approximately 4 weeks when stored at -20 degrees Celsius. For step-by-step reconstitution technique, see our guide to reconstituting research peptides.

The general reconstitution approach for a 10 mg vial is as follows. Allow the vial to equilibrate to room temperature before opening to prevent moisture condensation on the lyophilized cake. Add bacteriostatic water slowly against the glass wall (not directly onto the powder) using a sterile insulin syringe. Swirl gently; do not vortex, as mechanical shear can aggregate peptide chains. The solution should become clear within 60-90 seconds with no visible particulate matter. If cloudiness persists, allow an additional 5 minutes at room temperature before reassessing.

Worked reconstitution and dilution examples

Example 1: Stock solution at 1 mg/mL. Add 10 mL of bacteriostatic water to a 10 mg vial. Each 0.1 mL (100 microliters) of this stock contains 100 micrograms (0.1 mg) of hexarelin acetate. This concentration is appropriate for rodent in-vivo injection volumes of 100-200 microliters per dose.

Example 2: Molar stock for in-vitro receptor binding assay. Target concentration: 1 micromolar (1 microM). Molecular weight (free base) = 887.05 g/mol. For 10 mL of 1 microM stock: mass needed = (1 x 10^-6 mol/L) x (0.010 L) x (887.05 g/mol) = 8.87 micrograms. Using the 1 mg/mL stock from Example 1, dilute 8.87 microliters into 8991 microliters of assay buffer. This provides a working stock for further serial dilutions spanning 0.001 to 1000 nM.

Example 3: Research dose preparation for a typical rat study. Literature-reported research doses in rat GH-axis studies range from 40 to 80 micrograms/kg subcutaneously. For a 300 g rat at 80 micrograms/kg: dose = 80 x 0.3 = 24 micrograms. Using the 1 mg/mL stock, withdraw 24 microliters and dilute to 200 microliters with saline for subcutaneous injection. The final concentration in the syringe is 0.12 mg/mL. For additional guidance on scaling and adjusting these calculations to different body weights and animal cohorts, see our research peptide dosage calculation guide.

Literature-reported research doses (animal studies)

In rodent models, the majority of published GH-axis studies have used subcutaneous or intraperitoneal doses in the range of 40-160 micrograms/kg for single-injection challenge protocols. ^{[5] [13]} Chronic infusion protocols (via osmotic minipump) in cardiac remodeling models have used 50-100 micrograms/kg/day, with study durations of four to eight weeks. ^[8] For in-vitro pituitary cell studies, concentrations producing half-maximal GH secretion (EC50) cluster around 0.1-1 nM, with maximal responses at 10-100 nM. ^[24]

Human clinical trial literature from the 1990s used IV bolus doses of 0.5-2.0 micrograms/kg and subcutaneous doses of 1-4 micrograms/kg for GH provocative testing. ^{[16] [3]} These values appear in pharmacological reference texts and are cited here only for contextual comparison to the animal research literature. They do not constitute any form of guidance for non-research use.

Side Effects and Safety

Adverse effects observed in published clinical pharmacology studies

Clinical pharmacology studies of hexarelin conducted in the 1990s as part of pharmaceutical development (the compound reached Phase II clinical trials before development was halted for commercial rather than safety reasons) documented several consistent adverse effects at the doses studied.

The most frequently reported adverse effect in human subjects was cortisol and ACTH elevation. Hexarelin, unlike GHRH, produces measurable increases in plasma ACTH and cortisol in most subjects, likely via GHSR-1a engagement in the hypothalamic-pituitary-adrenal (HPA) axis and/or direct adrenal cortex stimulation. ^[3] In rat models, this adrenocortical activation is dose-dependent and attenuates with repeated administration in parallel with GH tachyphylaxis, suggesting shared receptor mechanisms.

Prolactin elevation was also documented in a subset of human subjects, consistent with GHSR-1a expression on lactotroph cells in the anterior pituitary. ^[16] Water retention and mild peripheral edema, attributable to IGF-1-mediated renal sodium reabsorption downstream of GH release, were reported in subjects receiving multiple-day dosing regimens in clinical pharmacology studies.

Cardiovascular effects observed in published research include a transient increase in heart rate and a modest reduction in mean arterial pressure following IV administration, consistent with the compound's CD36-mediated effects on vascular tone. ^[22] These effects were short-lived (resolving within 60-90 minutes) in the clinical studies reported.

Tachyphylaxis and receptor desensitization

As documented in the Muccioli et al. (1998) receptor study described above, repeated administration leads to GHSR-1a downregulation and progressive attenuation of GH response. ^[24] This is not a toxicological concern per se, but it represents a significant confound for longitudinal animal studies. Researchers planning multi-week in-vivo experiments should design protocols that account for desensitization, either by incorporating washout periods of at least seven days between stimulation cycles or by measuring receptor expression at study termination.

Plasma stability and degradation products

The D-amino acid substitutions in hexarelin substantially reduce, but do not eliminate, plasma peptidase-mediated degradation. Degradation products have not been characterized for biological activity in detail. One study using mass spectrometry-based metabolite tracking in rat plasma detected two primary degradation fragments corresponding to N-terminal and C-terminal cleavage products that showed no GHSR-1a binding activity in receptor competition assays. ^[12] The absence of biologically active metabolites simplifies pharmacokinetic interpretation but should be confirmed in the specific biological matrix used in each research application.

How It Compares

Hexarelin versus GHRP-2

GHRP-2 is the closest structural analogue to hexarelin in the GHRP class and is often selected as a comparator in receptor studies. Both are synthetic hexapeptides with high GHSR-1a affinity, but GHRP-2 lacks the 2-methyl modification on the D-tryptophan at position two. The functional consequence is approximately two-fold lower GH-releasing potency for GHRP-2 in head-to-head animal studies. ^[5] GHRP-2 shows less HPA axis activation than hexarelin in equimolar comparisons, which makes it a better choice for researchers seeking isolated GH axis stimulation without adrenocortical confounds. Hexarelin is preferred when maximal GH signal amplitude is the experimental goal, or when CD36-related cardiac endpoints are being studied simultaneously.

Hexarelin versus Ipamorelin

Ipamorelin is a pentapeptide GHS with high GHSR-1a selectivity and minimal off-target effects on the HPA axis or prolactin. ^[7] This pharmacological cleanliness makes ipamorelin the preferred compound for researchers who want GH axis stimulation without confounding corticosteroid or prolactin signals. Hexarelin offers approximately three to four times larger GH pulses than ipamorelin at equimolar doses, but at the cost of greater endocrine selectivity. For experiments where the GH signal itself is the primary readout (e.g., somatotroph reserve testing, IGF-1 axis modeling), hexarelin's amplitude advantage outweighs ipamorelin's selectivity advantage. For experiments where GH is an effector and clean hormonal background is critical (e.g., metabolic or immune studies), ipamorelin is the better tool.

Hexarelin versus MK-677

MK-677 (ibutamoren mesylate) is a non-peptide, orally bioavailable GHSR-1a agonist with a 24-hour plasma half-life, making it useful for sustained GH/IGF-1 elevation models. ^[15] It does not engage CD36. For chronic GH axis activation studies where daily injections are impractical, MK-677 has a logistical advantage. Hexarelin is preferred in mechanistic experiments where the injection route and time-defined GH pulse are part of the experimental design, and whenever CD36 biology is a study endpoint.

Hexarelin versus GHRH analogues

GHRH analogues (sermorelin, CJC-1295, tesamorelin) act at the GHRH receptor rather than GHSR-1a, and they rely entirely on sufficient pituitary GHRH-R expression and low somatostatin tone to produce GH release. Hexarelin's partial somatostatin resistance means it generates larger GH pulses in aged or stressed animals where somatostatin tone is high. Combined hexarelin plus GHRH administration produces supra-additive GH release, a synergism widely exploited in research protocols designed to maximally characterize pituitary secretory reserve. ^[8] Researchers using hexarelin and GHRH combination protocols should be aware that the supra-additive response can saturate standard GH immunoassay ranges and may require sample dilution.

Where to Buy

Hexarelin Acetate 10mg is available from Apollo Peptide Sciences, a research-focused vendor with published HPLC and MS CoAs for each batch. See the full Hexarelin Acetate 10mg product page for the current batch CoA, lot information, and purchasing details.

Before purchasing any research peptide, we recommend reviewing our research peptide supplier evaluation guide for a systematic framework covering CoA standards, third-party testing practices, cold-chain shipping, and vendor transparency criteria. Apollo Peptide Sciences is included in that guide with a full vendor profile.

For researchers who may also be evaluating related GH secretagogues, the GHRP-2 product page, ipamorelin product page, and MK-677 product page include similar evidence-based reviews with direct comparisons where published data support them.

Pricing and value context

At $70.00 for 10 mg, hexarelin acetate from Apollo Peptide Sciences is competitively positioned relative to the broader research peptide market. A 10 mg vial at a stock concentration of 1 mg/mL provides 100 doses at the 100 microgram/mL concentration commonly used in rodent challenge studies, yielding a per-dose cost well below alternative purity-verified sources. For high-throughput in-vitro work requiring nanomolar concentrations, a single 10 mg vial can support hundreds of experimental wells before stock depletion.

Researchers considering larger-scale studies (multi-cohort, multi-timepoint designs with large animal group sizes) may benefit from requesting bulk pricing or multiple vials from the same lot to ensure batch-to-batch consistency across a long experimental timeline.

Open Research Questions

Despite the relatively large published literature on hexarelin compared to most synthetic GHS peptides, several mechanistic and translational questions remain genuinely open as of 2026.

The precise structural basis for CD36 binding by hexarelin has not been resolved by crystallography or cryo-EM. Computational docking models suggest the Trp-D-Phe motif engages the lipid-binding groove of CD36, but experimental structure-activity relationship (SAR) data are sparse. ^[6] Without a resolved binding structure, rational design of hexarelin analogues with CD36 selectivity independent of GHSR-1a remains a trial-and-error exercise.

The relationship between hexarelin and the central regulation of sleep architecture is also incompletely understood. The Frieboes study documented SWS enhancement, but the downstream neurochemical pathway connecting GHSR-1a activation in hypothalamic sleep nuclei to polysomnographic slow-wave activity has not been mapped in detail. Whether this effect is mediated primarily via GH-GHRH feedback loops, direct GHSR-1a action on GABAergic neurons, or somatostatin tone modulation remains unclear. ^[11]

Tachyphylaxis mechanisms at the receptor level have been attributed to GHSR-1a downregulation and uncoupling (internalization and reduced G-protein coupling efficiency), but the relative contributions of receptor internalization versus beta-arrestin-mediated desensitization versus transcriptional receptor downregulation have not been quantified for hexarelin specifically. This distinction matters for drug development because biased agonists that minimize beta-arrestin recruitment could theoretically maintain GH-releasing activity without tachyphylaxis. ^[26]

Finally, the long-term effects of hexarelin on IGF-1-sensitive tissues in aged animal models have not been adequately characterized with survival endpoints. Most published studies use acute or subchronic (4-8 week) designs. Whether chronic low-dose GHSR-1a stimulation in aged rodents produces beneficial effects on physical function, lifespan, or pathological aging biomarkers (similar to effects observed with mild caloric restriction or genetic GH pathway modulation) is an active but incompletely addressed area of investigation.

Pharmacological Context, Placing Hexarelin in the GH Axis

The hypothalamic-pituitary-somatotropic axis is regulated by a two-peptide push-pull system: GHRH stimulates GH release, and somatostatin inhibits it. Endogenous ghrelin, produced in gastric X/A cells and to a lesser degree in the hypothalamus, provides a third input that potentiates GHRH action and inhibits somatostatin tone simultaneously. ^[4] Hexarelin pharmacologically mimics and amplifies this third input while resisting somatostatin suppression more effectively than GHRH alone.

The downstream consequences of somatotroph stimulation extend well beyond plasma GH elevation. GH acutely stimulates IGF-1 production in the liver (and locally in muscle, bone, and connective tissue), promotes lipolysis in adipose tissue, antagonizes insulin action in peripheral tissues, and stimulates nitrogen retention in muscle. ^[4] These effects make hexarelin-driven GH pulses broadly relevant to metabolic research, tissue repair models, and aging biology. Understanding hexarelin's pharmacology therefore requires familiarity with the entire somatotropic axis, not just receptor binding at the pituitary.

The GH axis also shows prominent sexual dimorphism in both expression patterns and functional regulation. Pulsatile GH release is more pronounced in males (larger pulse amplitude, more distinct inter-pulse nadirs), while females show higher baseline GH with smaller pulses. This dimorphism affects how hexarelin challenge tests should be interpreted in mixed-sex experimental cohorts. Most published hexarelin studies used exclusively male animals or subjects, which is a recognized limitation of the literature base. Researchers studying sex-specific outcomes should pilot-test hexarelin responsiveness in both sexes under their specific experimental conditions before designing definitive studies.

The concept of somatotropic axis "reserve" is central to understanding why hexarelin serves as a useful pharmacological probe. Reserve capacity (the difference between basal GH secretion and maximal stimulated GH secretion) declines with age, obesity, and hypothalamic-pituitary damage. Hexarelin challenge tests, because they produce near-maximal somatotroph stimulation, provide a sensitive measure of this reserve. Research groups using hexarelin as a provocative test agent in aging models should establish age-matched normative response curves in their specific animal strain and housing conditions, since even identical strain animals show significant inter-laboratory variability in GH pulse amplitude under standardized challenge conditions.

FAQ